AU2016215505B8 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders - Google Patents

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders Download PDF

Info

Publication number
AU2016215505B8
AU2016215505B8 AU2016215505A AU2016215505A AU2016215505B8 AU 2016215505 B8 AU2016215505 B8 AU 2016215505B8 AU 2016215505 A AU2016215505 A AU 2016215505A AU 2016215505 A AU2016215505 A AU 2016215505A AU 2016215505 B8 AU2016215505 B8 AU 2016215505B8
Authority
AU
Australia
Prior art keywords
ser
val
leu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215505A
Other languages
English (en)
Other versions
AU2016215505A1 (en
AU2016215505B2 (en
AU2016215505A2 (en
Inventor
Alan Gill
Cynthia A. Gill
Bingbing Jiang
John M. Lincecum
Steven N. Perrin
Fernando G. Vieira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALS Therapy Development Institute
Original Assignee
Als Therapy Development Inst
ALS Therapy Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst, ALS Therapy Development Institute filed Critical Als Therapy Development Inst
Publication of AU2016215505A1 publication Critical patent/AU2016215505A1/en
Publication of AU2016215505A2 publication Critical patent/AU2016215505A2/en
Publication of AU2016215505B2 publication Critical patent/AU2016215505B2/en
Application granted granted Critical
Publication of AU2016215505B8 publication Critical patent/AU2016215505B8/en
Priority to AU2022200323A priority Critical patent/AU2022200323B2/en
Priority to AU2024204572A priority patent/AU2024204572A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
AU2016215505A 2015-02-03 2016-02-02 Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders Active AU2016215505B8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022200323A AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111261P 2015-02-03 2015-02-03
US62/111,261 2015-02-03
PCT/US2016/016165 WO2016126702A1 (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200323A Division AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Publications (4)

Publication Number Publication Date
AU2016215505A1 AU2016215505A1 (en) 2017-07-27
AU2016215505A2 AU2016215505A2 (en) 2019-01-24
AU2016215505B2 AU2016215505B2 (en) 2021-10-28
AU2016215505B8 true AU2016215505B8 (en) 2021-11-11

Family

ID=56564599

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016215505A Active AU2016215505B8 (en) 2015-02-03 2016-02-02 Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
AU2022200323A Active AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A Pending AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022200323A Active AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A Pending AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Country Status (15)

Country Link
US (6) US10106618B2 (https=)
EP (2) EP4071175A1 (https=)
JP (4) JP6797810B2 (https=)
KR (2) KR20250007045A (https=)
CN (2) CN114195895B (https=)
AU (3) AU2016215505B8 (https=)
CA (1) CA2974135A1 (https=)
DK (1) DK3253412T3 (https=)
GB (1) GB2552429A (https=)
IL (3) IL322241A (https=)
MA (1) MA41459A (https=)
MX (2) MX392480B (https=)
RU (1) RU2727646C2 (https=)
SG (2) SG10201912752QA (https=)
WO (1) WO2016126702A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
RS66218B1 (sr) * 2019-07-01 2024-12-31 Tonix Pharma Ltd Anti-cd154 antitela i njihove upotrebe
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022150452A1 (en) * 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
KR20230108156A (ko) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Cd40l에 특이적으로 결합하는 항체 및 그의 용도
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056068A1 (en) * 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
ES2143553T3 (es) 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN1247472A (zh) 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
BR9809641A (pt) 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
JP2002510643A (ja) 1998-04-03 2002-04-09 トラスティーズ・オブ・ダートマス・カレッジ 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2390412A1 (en) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
EP1284747A2 (en) * 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040146949A1 (en) 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
WO2005003174A1 (en) 2003-07-08 2005-01-13 Genesto A/S BINDING MEMBER TOWARDS PNEUMOCOCCUS SURFACE ADHESIN A PROTEIN (PsaA)
CA2533593A1 (en) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Altered antibodies having improved antigen-binding affinity
AU2004266159A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP2008535841A (ja) * 2005-04-06 2008-09-04 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法
WO2006138316A2 (en) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methods for delivering molecules to the central nervous system
KR100772247B1 (ko) 2005-11-04 2007-11-01 엘지전자 주식회사 평면 디스플레이 기기 및 평면 디스플레이 기기의 냉각장치
WO2007059332A2 (en) 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Platelet aggregation assays
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
US7647438B1 (en) * 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
GB0815788D0 (en) 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
WO2012009705A1 (en) * 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012103218A1 (en) 2011-01-25 2012-08-02 University Of South Florida A transgenic model of alzheimer's disease
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2832281C (en) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN103998995B (zh) 2011-12-08 2016-12-28 普雷斯弗雷克斯股份公司 低体积精密波纹管
WO2013169338A1 (en) 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
CN105121621B (zh) 2012-10-18 2019-08-02 张永新 用于细胞动静态交替培养的生物反应器系统及其方法
CN105246914B (zh) * 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
EP3041863A4 (en) * 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CN106132429A (zh) 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR102840867B1 (ko) 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056068A1 (en) * 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS PATRICIA M ET AL, "Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity", JOURNAL OF RHEUMATOLOGY (2007-11-01), vol. 34, no. 11, pages 2204 - 2210 *
J. H. XIE ET AL, "Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases", THE JOURNAL OF IMMUNOLOGY, (2014-03-26), vol. 192, no. 9, doi:10.4049/jimmunol.1303239, ISSN 0022-1767, pages 4083 - 4092 *

Also Published As

Publication number Publication date
JP6797810B2 (ja) 2020-12-09
KR20250007045A (ko) 2025-01-13
US20250263493A1 (en) 2025-08-21
CN114195895A (zh) 2022-03-18
RU2017126997A3 (https=) 2019-09-19
GB201713871D0 (en) 2017-10-11
RU2017126997A (ru) 2019-03-04
AU2016215505A1 (en) 2017-07-27
AU2016215505B2 (en) 2021-10-28
US20210269538A1 (en) 2021-09-02
US20170342158A1 (en) 2017-11-30
JP2021054826A (ja) 2021-04-08
CN108064168B (zh) 2021-10-26
KR102747565B1 (ko) 2024-12-27
SG10201912752QA (en) 2020-02-27
EP3253412B1 (en) 2022-03-23
IL253571B (en) 2022-04-01
US20190092868A1 (en) 2019-03-28
US20200277391A1 (en) 2020-09-03
US20240043549A1 (en) 2024-02-08
MX392480B (es) 2025-03-24
JP2025081304A (ja) 2025-05-27
CN114195895B (zh) 2024-09-06
EP4071175A1 (en) 2022-10-12
WO2016126702A1 (en) 2016-08-11
MA41459A (fr) 2017-12-12
AU2024204572A1 (en) 2024-09-19
NZ733621A (en) 2024-07-05
US11014990B2 (en) 2021-05-25
AU2022200323B2 (en) 2024-07-25
CN108064168A (zh) 2018-05-22
US11692040B2 (en) 2023-07-04
AU2016215505A2 (en) 2019-01-24
IL253571A0 (en) 2017-09-28
US10683356B2 (en) 2020-06-16
DK3253412T3 (da) 2022-05-23
IL287823A (en) 2022-01-01
JP2018510132A (ja) 2018-04-12
EP3253412A4 (en) 2018-08-01
RU2727646C2 (ru) 2020-07-22
US12275793B2 (en) 2025-04-15
IL322241A (en) 2025-09-01
SG11201706258WA (en) 2017-08-30
GB2552429A (en) 2018-01-24
KR20170108024A (ko) 2017-09-26
US10106618B2 (en) 2018-10-23
CA2974135A1 (en) 2016-08-11
EP3253412A1 (en) 2017-12-13
JP2023036717A (ja) 2023-03-14
MX2022005655A (es) 2022-06-29
MX2017009694A (es) 2018-03-15
AU2022200323A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
AU2022200323B2 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
BRPI0924058B1 (pt) Anticorpos monoclonais, seus usos, bem como composição farmacêutica
CN114007645B (zh) 修饰的抗pd-l1抗体及用于治疗神经退行性疾病的方法和用途
KR20230012538A (ko) 만성 질환에 의한 빈혈을 치료하기 위한 항-헤모주벨린 (hjv) 항체
KR20240105408A (ko) Covid-19의 치료 및 예방을 위한 조성물
CN112805301A (zh) 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
CN119768431A (zh) Igf1r抗体
HK40083008A (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
HK1245633B (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
HK1245633A1 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
WO2023183926A1 (en) Anti-cd94 antibodies and methods of use thereof
HK40106636A (zh) 抗c1s抗体和其用途
HK40106636B (zh) 抗c1s抗体和其用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 DEC 2018

TH Corrigenda

Free format text: IN VOL 35 , NO 43 , PAGE(S) 8452 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ALS THERAPY DEVELOPMENT INSTITUTE, APPLICATION NO. 2016215505, UNDER INID (56) INSERT WO 2013056068 A1

FGA Letters patent sealed or granted (standard patent)